{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:52:16Z","timestamp":1774954336196,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Danish Council for Independent Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.bcp.2021.114782","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T02:16:31Z","timestamp":1632190591000},"page":"114782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Discovery and functional characterization of N-(thiazol-2-yl)-benzamide analogs as the first class of selective antagonists of the Zinc-Activated Channel (ZAC)"],"prefix":"10.1016","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0841-545X","authenticated-orcid":false,"given":"Nawid","family":"Madjroh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Mellou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3973-3143","authenticated-orcid":false,"given":"Paul A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pella C.","family":"S\u00f6derhielm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7927-5052","authenticated-orcid":false,"given":"Anders A.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.bcp.2021.114782_b0005","first-page":"S142","article-title":"THE CONCISE GUIDE TO PHARMACOLOGY 2019\/20: Ion channels","volume":"176","author":"Alexander","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.bcp.2021.114782_b0010","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pharmthera.2010.07.001","article-title":"5-HT3 receptors: role in disease and target of drugs","volume":"128","author":"Walstab","year":"2010","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bcp.2021.114782_b0015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/pr.118.015487","article-title":"5-HT3 receptor antagonists in neurologic and neuropsychiatric disorders: The iceberg still lies beneath the surface","volume":"71","author":"Fakhfouri","year":"2019","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bcp.2021.114782_b0020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/bs.apha.2017.01.003","article-title":"Glycine Receptor Drug Discovery","volume":"79","author":"Lynch","year":"2017","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.bcp.2021.114782_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.apha.2017.03.003","article-title":"GABAA Receptors and the Diversity in their Structure and Pharmacology","volume":"79","author":"Chua","year":"2017","journal-title":"Adv Pharmacol"},{"issue":"8","key":"10.1016\/j.bcp.2021.114782_b0030","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.tips.2018.04.003","article-title":"An Emerging Circuit Pharmacology of GABAA Receptors","volume":"39","author":"Engin","year":"2018","journal-title":"Trends Pharmacol Sci"},{"issue":"9","key":"10.1016\/j.bcp.2021.114782_b0035","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nrd2927","article-title":"Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system","volume":"8","author":"Taly","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.bcp.2021.114782_b0040","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1113\/JP275101","article-title":"Molecular function of \u03b17 nicotinic receptors as drug targets","volume":"596","author":"Bouzat","year":"2018","journal-title":"J Physiol"},{"issue":"7514","key":"10.1016\/j.bcp.2021.114782_b0045","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nature13552","article-title":"X-ray structure of the mouse serotonin 5-HT3 receptor","volume":"512","author":"Hassaine","year":"2014","journal-title":"Nature"},{"issue":"7625","key":"10.1016\/j.bcp.2021.114782_b0050","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nature19785","article-title":"X-ray structure of the human \u03b14\u03b22 nicotinic receptor","volume":"538","author":"Morales-Perez","year":"2016","journal-title":"Nature"},{"issue":"7740","key":"10.1016\/j.bcp.2021.114782_b0055","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-018-0833-4","article-title":"Cryo-EM structure of the human \u03b11\u03b23\u03b32 GABAA receptor in a lipid bilayer","volume":"565","author":"Laverty","year":"2019","journal-title":"Nature"},{"issue":"7730","key":"10.1016\/j.bcp.2021.114782_b0060","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41586-018-0672-3","article-title":"Conformational transitions of the serotonin 5-HT3 receptor","volume":"563","author":"Polovinkin","year":"2018","journal-title":"Nature"},{"issue":"7349","key":"10.1016\/j.bcp.2021.114782_b0065","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nature10139","article-title":"Principles of activation and permeation in an anion-selective Cys-loop receptor","volume":"474","author":"Hibbs","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2021.114782_b0070","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.1038\/ncomms7829","article-title":"The desensitization gate of inhibitory Cys-loop receptors","volume":"6","author":"Gielen","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.bcp.2021.114782_b0075","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/bs.apha.2014.10.002","article-title":"Allosteric modulation of GABAA receptors via multiple drug-binding sites","volume":"72","author":"Sieghart","year":"2015","journal-title":"Adv Pharmacol"},{"issue":"1","key":"10.1016\/j.bcp.2021.114782_b0080","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coph.2011.01.010","article-title":"Allosteric modulation of the 5-HT3 receptor","volume":"11","author":"Davies","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.bcp.2021.114782_b0085","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1476-5381.2011.01471.x","article-title":"Allosteric modulation of glycine receptors","volume":"164","author":"Yevenes","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.bcp.2021.114782_b0090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bcpt.12361","article-title":"Targeting \u03b14\u03b22 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach","volume":"116","author":"Grupe","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.bcp.2021.114782_b0095","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.bcp.2015.07.028","article-title":"Allosteric modulation of nicotinic acetylcholine receptors","volume":"97","author":"Chatzidaki","year":"2015","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.bcp.2021.114782_b0100","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.tibs.2021.01.011","article-title":"Direct Structural Insights into GABAA Receptor Pharmacology","volume":"46","author":"Kim","year":"2021","journal-title":"Trends Biochem Sci"},{"issue":"2","key":"10.1016\/j.bcp.2021.114782_b0105","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1074\/jbc.M208814200","article-title":"A novel class of ligand-gated ion channel is activated by Zn2+","volume":"278","author":"Davies","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2021.114782_b0110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bcp.2016.02.004","article-title":"Copper and protons directly activate the zinc-activated channel","volume":"103","author":"Trattnig","year":"2016","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.bcp.2021.114782_b0115","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.bbrc.2005.07.079","article-title":"Cloning and expression of ligand-gated ion-channel receptor L2 in central nervous system","volume":"335","author":"Houtani","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bcp.2021.114782_b0120","series-title":"Modulators of Zinc Activated Channel (US 2019\/0022121 A1)","author":"Chang","year":"2019"},{"key":"10.1016\/j.bcp.2021.114782_b0125","doi-asserted-by":"crossref","first-page":"105653","DOI":"10.1016\/j.phrs.2021.105653","article-title":"Delineation of the functional properties exhibited by the Zinc-Activated Channel (ZAC) and its high-frequency Thr128Ala variant (rs2257020) in Xenopus oocytes","volume":"169","author":"Madjroh","year":"2021","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.bcp.2021.114782_b0130","doi-asserted-by":"crossref","first-page":"e0210182","DOI":"10.1371\/journal.pone.0210182","article-title":"Curare alkaloids from Matis Dart Poison: Comparison with d-tubocurarine in interactions with nicotinic, 5-HT3 serotonin and GABAA receptors","volume":"14","author":"Spirova","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2021.114782_b0135","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1213\/ane.0b013e31817b4469","article-title":"Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors","volume":"107","author":"Liu","year":"2008","journal-title":"Anesth Analg"},{"issue":"30","key":"10.1016\/j.bcp.2021.114782_b0140","doi-asserted-by":"crossref","first-page":"25241","DOI":"10.1074\/jbc.M112.360370","article-title":"Discovery of a novel allosteric modulator of 5-HT3 receptors: Inhibition and potentiation of Cys-loop receptor signaling through a conserved transmembrane intersubunit site","volume":"287","author":"Trattnig","year":"2012","journal-title":"J Biol Chem"},{"issue":"13","key":"10.1016\/j.bcp.2021.114782_b0145","doi-asserted-by":"crossref","first-page":"10141","DOI":"10.1074\/jbc.M109.079319","article-title":"Ginkgolide X is a potent antagonist of anionic Cys-loop receptors with a unique selectivity profile at glycine receptors","volume":"285","author":"Jensen","year":"2010","journal-title":"J Biol Chem"},{"issue":"47","key":"10.1016\/j.bcp.2021.114782_b0150","doi-asserted-by":"crossref","first-page":"33708","DOI":"10.1074\/jbc.M113.509356","article-title":"Elucidation of molecular impediments in the \u03b16 subunit for in vitro expression of functional \u03b16\u03b24* nicotinic acetylcholine receptors","volume":"288","author":"Jensen","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2021.114782_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114781","article-title":"Probing the molecular basis for signal transduction through the Zinc-Activated Channel (ZAC)","volume":"193","author":"Madjroh","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"10.1016\/j.bcp.2021.114782_b0160","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.bcp.2004.02.013","article-title":"Pharmacological characterization of human excitatory amino acid transporters EAAT1, EAAT2 and EAAT3 in a fluorescence-based membrane potential assay","volume":"67","author":"Jensen","year":"2004","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"10.1016\/j.bcp.2021.114782_b0165","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.bcp.2003.12.037","article-title":"Functional characterisation of the human \u03b11 glycine receptor in a fluorescence-based membrane-potential assay","volume":"67","author":"Jensen","year":"2004","journal-title":"Biochem Pharmacol"},{"issue":"6454","key":"10.1016\/j.bcp.2021.114782_b0170","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/366479a0","article-title":"Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities","volume":"366","author":"Eisel\u00e9","year":"1993","journal-title":"Nature"},{"issue":"6649","key":"10.1016\/j.bcp.2021.114782_b0175","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/38738","article-title":"Sites of alcohol and volatile anaesthetic action on GABAA and glycine receptors","volume":"389","author":"Mihic","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2021.114782_b0180","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bcp.2016.04.004","article-title":"Delineation of the functional properties and the mechanism of action of TMPPAA, an allosteric agonist and positive allosteric modulator of 5-HT3 receptors","volume":"110-111","author":"Gasiorek","year":"2016","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.bcp.2021.114782_b0185","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1021\/acschemneuro.8b00028","article-title":"Characterization of a 5-HT3-ELIC Chimera Revealing the Sites of Action of Modulators","volume":"9","author":"Price","year":"2018","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bcp.2021.114782_b0190","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.neuropharm.2017.08.007","article-title":"A chimeric prokaryotic-eukaryotic pentameric ligand gated ion channel reveals interactions between the extracellular and transmembrane domains shape neurosteroid modulation","volume":"125","author":"Ghosh","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2021.114782_b0195","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fnmol.2016.00041","article-title":"The intracellular loop of the glycine receptor: It's not all about the size","volume":"9","author":"Langlhofer","year":"2016","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"10.1016\/j.bcp.2021.114782_b0200","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0896-6273(01)00558-X","article-title":"Structure of GABARAP in two conformations: implications for GABAA receptor localization and tubulin binding","volume":"33","author":"Coyle","year":"2002","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.bcp.2021.114782_b0205","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1124\/mol.116.103432","article-title":"Dipicrylamine modulates GABA\u03c11 receptors through interactions with residues in the TM4 and Cys-loop domains","volume":"89","author":"Limon","year":"2016","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2021.114782_b0210","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/mol.115.099291","article-title":"A multifaceted GABAA receptor modulator: Functional properties and molecular mechanism of action of the sedative-hypnotic and recreational drug methaqualone (Quaalude)","volume":"88","author":"Hammer","year":"2015","journal-title":"Mol Pharmacol"},{"issue":"7118","key":"10.1016\/j.bcp.2021.114782_b0215","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nature05324","article-title":"Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites","volume":"444","author":"Hosie","year":"2006","journal-title":"Nature"},{"issue":"45","key":"10.1016\/j.bcp.2021.114782_b0220","doi-asserted-by":"crossref","first-page":"11599","DOI":"10.1523\/JNEUROSCI.3467-06.2006","article-title":"Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog","volume":"26","author":"Li","year":"2006","journal-title":"J Neurosci"},{"issue":"17","key":"10.1016\/j.bcp.2021.114782_b0225","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1523\/JNEUROSCI.21-17-06561.2001","article-title":"The C terminus of the human nicotinic \u03b14\u03b22 receptor forms a binding site required for potentiation by an estrogenic steroid","volume":"21","author":"Paradiso","year":"2001","journal-title":"J Neurosci"},{"issue":"7330","key":"10.1016\/j.bcp.2021.114782_b0230","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature09647","article-title":"X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel","volume":"469","author":"Nury","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bcp.2021.114782_b0235","doi-asserted-by":"crossref","first-page":"e0157700","DOI":"10.1371\/journal.pone.0157700","article-title":"Kavain, the major constituent of the anxiolytic kava extract, potentiates GABAA Receptors: Functional characteristics and molecular mechanism","volume":"11","author":"Chua","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2021.114782_b0240","doi-asserted-by":"crossref","unstructured":"Halliwell RF, Peters JA, Lambert JJ. The mechanism of action and pharmacological specificity of the anticonvulsant NMDA antagonist MK-801: a voltage clamp study on neuronal cells in culture. Br J Pharmacol 1989;96:480-94.","DOI":"10.1111\/j.1476-5381.1989.tb11841.x"},{"key":"10.1016\/j.bcp.2021.114782_b0245","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1113\/jphysiol.1993.sp019643","article-title":"Multiple mechanisms of picrotoxin block of GABA-induced currents in rat hippocampal neurons","volume":"464","author":"Yoon","year":"1993","journal-title":"J Physiol"},{"issue":"4","key":"10.1016\/j.bcp.2021.114782_b0250","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bcp.2005.04.035","article-title":"Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain","volume":"70","author":"Winquist","year":"2005","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"10.1016\/j.bcp.2021.114782_b0255","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1523\/JNEUROSCI.5565-10.2011","article-title":"Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors","volume":"31","author":"Hansen","year":"2011","journal-title":"J Neurosci"},{"issue":"15","key":"10.1016\/j.bcp.2021.114782_b0260","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1016\/j.bmcl.2009.05.123","article-title":"Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benza mide and its biological evaluation","volume":"19","author":"Uto","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"issue":"02","key":"10.1016\/j.bcp.2021.114782_b0265","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/a-0654-5074","article-title":"Synthesis, Antioxidant and In-Silico Studies of Potent Urease Inhibitors: N-(4-{[(4-Methoxyphenethyl)-(substituted)amino]sulfonyl}phenyl)acetamides","volume":"69","author":"Abbasi","year":"2019","journal-title":"Drug Res (Stuttg)"},{"issue":"7","key":"10.1016\/j.bcp.2021.114782_b0270","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1016\/j.bmc.2009.02.038","article-title":"Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators","volume":"17","author":"Iino","year":"2009","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"10.1016\/j.bcp.2021.114782_b0275","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1021\/jm1008659","article-title":"Discovery of phosphoric acid mono-{2-[(E\/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist","volume":"54","author":"Sams","year":"2011","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/j.bcp.2021.114782_b0280","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1016\/j.bmcl.2009.07.097","article-title":"Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzam ide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist","volume":"19","author":"Satoh","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"issue":"20","key":"10.1016\/j.bcp.2021.114782_b0285","doi-asserted-by":"crossref","first-page":"8393","DOI":"10.1158\/0008-5472.CAN-08-1915","article-title":"Small molecule targeting the Hec1\/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal","volume":"68","author":"Wu","year":"2008","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.bcp.2021.114782_b0290","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1021\/jm0003945","article-title":"Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists","volume":"44","author":"van Muijlwijk-Koezen","year":"2001","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.bcp.2021.114782_b0295","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.3390\/molecules23112884","article-title":"Identification and Characterization of NTB451 as a Potential Inhibitor of Necroptosis","volume":"23","author":"In","year":"2018","journal-title":"Molecules"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221003981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221003981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:34:31Z","timestamp":1757770471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221003981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":59,"alternative-id":["S0006295221003981"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114782","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and functional characterization of N-(thiazol-2-yl)-benzamide analogs as the first class of selective antagonists of the Zinc-Activated Channel (ZAC)","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114782","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114782"}}